ABBV Stock Price Today (May 2026) — AbbVie Inc. Analysis & Key Metrics 2026-05-22
AbbVie Inc. (ABBV) is trading at $215.70, up 0.56% today (as of May 2026). The stock continues to show early recovery signs above the short-term average, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $250.33 (16.1% upside).
- Volatility remains elevated (14.84% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (12.40% YoY) alongside significant competitive pressures.
ABBV Stock Analysis: Key Metrics & Valuation (May 2026)
Concise, actionable data for investors
AbbVie Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $428.49B
P/E Ratio
Forward P/E: 12.77
Revenue Growth
Year over Year
Analyst Target
+16.1% upside potential
Key Investor Questions About ABBV
What investors need to know before buying
Based on current market data, ABBV presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 66.84)
- Fundamentals say: Mixed signals (nuanced financial profile)
ABBV's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ABBV investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $68.40B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, ABBV stock traded between $176.57 and $244.81—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 14.84% annualized volatility and β=0.36, the stock exhibits low sensitivity to market moves—making ABBV suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
AbbVie Expands European Reach As Investors Weigh Dividend Support
AbbVie received a positive opinion from the European Medicines Agency's CHMP for Boey for glabellar lines and MAVIRET for acute hepatitis C infection, supporting potential approvals in Europe. The company plans to share new oncology data at the upcoming ASCO Annual Meeting and recently reported strong clinical updates in inflammatory bowel disease therapies. These developments highlight AbbVie's expanding presence in aesthetics, antivirals and immunology alongside upcoming oncology...
The Dividend Stocks That Generate $60,000 Tax-Free Inside a Roth (And What They Cost You in a Taxable Account)
Holding a high-yield dividend portfolio in a taxable account at the 24% federal bracket means writing the IRS a $14,400 check every year on $60,000 of income that should have been yours. It repeats annually, forever, on the same dollars you already earned. This series exists because most readers know what a Roth IRA is ... The Dividend Stocks That Generate $60,000 Tax-Free Inside a Roth (And What They Cost You in a Taxable Account)
AbbVie (ABBV): 10 Best Low Risk Stocks to Buy in 2026
AbbVie Inc. (NYSE:ABBV) is one of the best low risk stocks to buy in 2026. On May 5, AbbVie presented 18 abstracts at the 2026 Digestive Disease Week Annual Meeting, highlighting new real-world and clinical trial data for its IBD therapies, Skyrizi (risankizumab) and Rinvoq (upadacitinib). The findings demonstrate the long-term efficacy, safety, and durability […]
The Smartest Growth Stocks to Invest $10,000 in As Investors Rotate Out of Tech
When investors take a risk-off attitude, stocks with attractive, growing dividends are often their safe-haven option.
3 Stocks That May Be Trading Below Their Estimated Value In May 2026
The United States market has experienced a flat week but has shown significant growth over the past year with a 27% increase, and earnings are anticipated to grow by 17% annually. In this context, identifying stocks that may be trading below their estimated value can offer opportunities for investors seeking to capitalize on potential future gains.
The Dividend Stocks That Can Replace a $65,000 Income and What They’ll Cost You
Replacing a real paycheck with dividends is the cleanest version of financial independence. The income target here is $65,000 per year, roughly the US median individual wage, and the question is whether a $650,000 portfolio can actually produce it. The honest answer up front: only by reaching past pure blue chips into higher-yield categories. Here ... The Dividend Stocks That Can Replace a $65,000 Income and What They’ll Cost You
Opinion: AbbVie Is the Best Dividend King to Buy in an Increasingly Uncertain Market
This big pharma stock checks off a lot of boxes.
3 Stocks That May Be Undervalued By The Market In May 2026
In the last week, the United States market has stayed flat, yet it is up 27% over the past year with earnings expected to grow by 17% per annum in the coming years. In this context, identifying stocks that may be undervalued by the market involves looking for companies whose intrinsic value might not be fully reflected in their current share prices despite these positive growth trends.
GSK Stock Declines 9% in a Month: Time to Buy, Hold or Exit?
GSK shares slide after Q1 despite earnings and sales beats, as investors weigh slowing legacy drug sales against strong Specialty Medicines growth.
Fifth Third Bancorp And 2 Stocks Possibly Undervalued For Consideration
In the last week, the United States market has stayed flat, yet it is up 27% over the past year with earnings forecasted to grow by 17% annually. In such an environment, identifying potentially undervalued stocks like Fifth Third Bancorp can offer investors opportunities for growth at a reasonable price.
Frequently Asked Questions
Common investor questions about AbbVie Inc.
AbbVie Inc. (ABBV) is currently trading at $215.70. The RSI (14-day) is at 66.8, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $250.33 implies 16.1% upside from current levels. Volatility is low at 14.8% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for AbbVie Inc. (ABBV): The trailing P/E ratio is 100.78, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 12.77, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.57, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is -111.68. Price-to-Sales is 5.82. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 30 analysts covering ABBV, the consensus price target is $250.33. This represents a 16.1% upside from the current price of $215.70. The range spans from a low target of $184.00 to a high target of $294.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, AbbVie Inc. (ABBV) pays a dividend with a current yield of approximately 3.21%. The annualized dividend rate is $6.74 per share. The payout ratio is 326.0%, which exceeds 100%—this means the company is paying out more than it earns, which may not be sustainable long-term. The most recent ex-dividend date was 2026-04-15.
Key risks for AbbVie Inc. (ABBV) investors include: 1. Unsustainable dividend payout ratio (326%) could lead to a dividend cut. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is AbbVie Inc.'s (ABBV) current debt and financial health profile: Total debt stands at $68.40B. The company holds $5.26B in cash and equivalents.